Coeptis Therapeutics, Inc.
NASDAQ:COEPBiotechnology
Healthcare
$14.64 +4.68%
+$0.73 today
- Market cap
- $57.63M
- Beta
- -0.43
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$1.97
52W Low $6.80High $21.41
Volume 0.18M
Average 0.05M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$8.60M
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$13.74M
FY 2025 · Annual
+140.6% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.45M) | (37.57M) | (21.27M) | (10.88M) | (11.92M) |
| Depreciation & Amortization | 447.41K | 1M | 1.04M | 1.04M | 1.22M |
| Deferred Income Tax | 5.34M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.9M | 0 | 477.5K | 1.1M | 1.22M |
| Change in Working Capital | (2.98M) | (550.34K) | 1.73M | (125.26K) | (1.46M) |
| Accounts Receivables | 21.79K | (8.08K) | (30.9K) | (234.74K) | (7.35K) |
| Inventory | (422.02K) | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.58M) | (35.07K) | 1.32M | (149.94K) | (381.01K) |
| Other Working Capital | (1M) | (507.19K) | 437.31K | 259.42K | (1.07M) |
| Other Non-Cash Items | 4.26M | 33.25M | 10.79M | 2.21M | 2.34M |
| Operating Cash Flow | (4.49M) | (3.88M) | (7.24M) | (6.65M) | (8.6M) |
| Capital Expenditures | (1.75M) | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.75M) | 0 | 0 | 0 | 0 |
| Debt Repayment | (1.62M) | (2.42M) | (575K) | 1.2M | 771.25K |
| Common Stock Issued | 10.14M | 3.27M | 5.29M | 100K | 12.97M |
| Common Stock Repurchased | (247.17K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (50.9K) | 4.63M | 200K | 500K | 0 |
| Financing Cash Flow | 8.22M | 5.49M | 4.92M | 5.71M | 13.74M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.98M | 1.61M | (2.32M) | (936.25K) | 5.14M |
| Free Cash Flow | (6.24M) | (3.88M) | (7.24M) | (6.65M) | (8.6M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$11.9M
+ D&A$1.2M
+ Stock-Based Comp$1.2M
+ Deferred Tax$0
- Working Capital-$1.5M
+ Other Non-Cash$2.3M
= Operating Cash Flow-$8.6M
- Capex$0
= Free Cash Flow-$8.6M
Analysis
FY2025 free cash flow is -$8.6M. FCF conversion is 72.2% of net income. Operating cash flow was -$8.6M, with capex of $0. The largest bridge item is Other Non-Cash at $2.3M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 424B3 | 424B3 filing | Jun 18, 2026 | |
| EFFECT | EFFECT filing | Jun 16, 2026 | |
| POS AM | POS AM filing | Jun 16, 2026 | |
| S-1 | S-1 filing | Jun 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 8, 2026 |
Does COEP generate free cash flow?
Coeptis Therapeutics, Inc. (COEP) generated -$8.60M of free cash flow in fiscal 2025.
How much operating cash flow does COEP produce?
Operating cash flow was -$8.60M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.